Article
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
Lung cancer (Amsterdam, Netherlands) - 1 May 2010
Onitsuka Takamitsu, Uramoto Hidetaka, Nose Naohiro, Takenoyama Mitsuhiro, Hanagiri Takeshi, Sugio Kenji, Yasumoto Kosei
Abstract excerpt
BACKGROUND: Some types of somatic mutation of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) are associated with a significant clinical response to a tyrosine kinase inhibitor (TKI). However, most of the patients with this type of sensitive mutations in their tumor show acquired resistance during the TKI treatment. METHODS: The mutations in exons 19-21 of the EGFR gene were...
Topics
- Aged
- Aged, 80 and over
- Carcinoma, Non-Small-Cell Lung
- DNA Mutational Analysis
- Disease Progression
- Drug Resistance, Neoplasm
- ErbB Receptors
- Exons
- Female
- Gefitinib